2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR

Recruiting

99 years or below

All

70 participants needed

1 Location

Brief description of study

This is an open-label, non-randomized trial that will be conducted at three clinical sites. The subject population will be patients undergoing transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) at Thomas Jefferson University, The University of California, San Diego, and University of Pennsylvania. Patients will receive a contrast-enhanced ultrasound (CEUS) exam the morning prior to embolization, approximately one week post-embolization, and at their one month MRI follow up. The goal is to determine if CEUS can detect residual viable tumor after TACE with greater reliability than MRI.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: ['Hepatocellular Carcinoma', 'Chemoembolization, Therapeutic']
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 828782

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR CARCINOMA CHEMOEMBOLIZATION

Brief description of study

Eligibility of study

Find a site

Interested in the study